Cidara Therapeutics Presents Preclinical Data For CD101 - Quick Facts

(RTTNews) - Cidara Therapeutics, Inc. (CDTX) announced the presentation of preclinical data from studies demonstrating the unique attributes of its lead antifungal drug candidate, CD101, supporting its potential use for treating serious fungal infections.

The results are being presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy or ICAAC and the International Congress of Chemotherapy or ICC joint meeting in San Diego, September 17-21, 2015.

According to the company, the preclinical studies demonstrate that CD101 is associated with high stability and solubility, potent antifungal activity with high efficacy in animal models, and no toxicity signals.

CD101 IV is currently in Phase 1 clinical development and was recently designated a Qualified Infectious Disease Product or QIDP with Fast Track status from the U.S. Food and Drug Administration for the treatment of candidemia and invasive candidiasis.